Blog
Home / Blog / FDA Approves First MRI-Guided Ultrasound Device to Treat Essential Tremor

FDA Approves First MRI-Guided Ultrasound Device to Treat Essential Tremor

By Nathan Reeves on July 12, 2016 | Leave a response
| Printer friendly version

The FDA recently approved INSIGHTEC’s Premarket Approval (“PMA”) application for ExAblate Neuro, a device designed to treat essential tremor.  Essential tremor is the most common kind of tremor; it commonly affects the hands, but can also affect other parts of the body.  The ExAblate Neuro uses magnetic resonance imaging (MRI) to guide a focused ultrasound beam to destroy a small part of the thalamus, a section of the brain thought to control some involuntary movements.  According to INSIGHTEC’s website, the “revolutionary non-invasive treatment offers a life changing treatment to patients with essential tremor, tremor dominant Parkinson’s Disease and neuropathic pain.”

neurosurgery_video

According to the FDA press release, the procedure works as follows:

To determine if the ExAblate Neuro treatment is appropriate, patients should first have MR and computerized tomography (CT) scans.  Those undergoing treatment with the MRI-guided device lie in an MRI scanner that takes images to help a doctor identify the targeted area in the brain’s thalamus for treatment.  Treatment with transcranial focused ultrasound energy is administered with incremental increases in energy until patients achieve a reduction of tremor.  Patients are awake and responsive during the entire treatment.

As noted in the press release, the FDA relied on a recently-presented study of the device’s effectiveness.  76 patients exhibiting symptoms of essential tremor participated in the study.  56 patients received the ExAblate Neuro treatment, whereas 20 patients received a placebo treatment.  Patients receiving INSIGHTEC’s ExAblate Neuro treatment showed a nearly 50% improvement after three months.  However, Patients who received the placebo treatment exhibited no improvement, and some experienced a slight worsening in symptoms.  Patients receiving the placebo treatment were able to “cross over” and join the treatment group after three months had elapsed.  All patients (including the “cross over” patients) who received the ExAblate Neuro treatment retained about 40% improvement after twelve months.  The study’s findings were presented at the 20th International Congress of Parkinson’s Disease and Movement Disorders.

Unfortunately, patients who cannot undergo an MRI, such as those with implantable metallic devices, are ineligible for the treatment.

Tagged
Nathan Reeves
Nathan Reeves is an associate in our Seattle office. He practices intellectual property law, with an emphasis on litigation. Mr. Reeves received his Bachelor's degrees from Walla Walla University, where he also conducted research in materials science. Mr. Reeves received his J.D. from Harvard Law School, where he worked as a clinical intern in the school's Cyberlaw Clinic and as Managing Editor of the Harvard Journal of Law & Public Policy. Mr. Reeves joined the firm in 2015. He has experience representing clients in fields ranging from software and web services, to satellite communications, to media and entertainment.
Click here to read full bio
View all posts published by Nathan Reeves »

Leave a Reply

By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.

Follow Us